Keywords
Last Name

Jean-Bosco Tagne, PhD

TitleAssistant Professor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionPulmonary, Allergy, Sleep & Critical Care Medicine
Address72 E. Concord St Housman (R)
Boston MA 02118
Phone(617) 638-4860
ORCID ORCID Icon0000-0003-1830-9156
 Research Expertise & Professional Interests
Research Special Interests/Projects:

TARGETS OF THE THYROID TRANSCRIPTION FACTOR 1 (TTF1, NKX2-1) A HOMEODOMAIN NECESSARY FOR NORMAL LUNG, THYROID AND BRAIN DEVELOPMENT AND OTHER LUNG REGULATORS IN LUNG DEVELOPMENT AND DISEASES.
One of the main goals of the research in our lab is to identify, characterize and understand the mechanisms of target gene regulation during lung development and lung diseases (Cao et al, J. Biol. Chem. 2010). We have used genome-wide approaches (Lee et al, Science. 2002 298 (5594), Harbison CT et al, Nature. 2004 431(7004), Workman C et al, Science 2006 312: 1054) to identify and map targets of the key lung epithelial transcription factor Nkx2.1 in the developing lung. This factor and some of their major targets are being altered in lung diseases such as cancer (Tagne et al, PLoS ONE, 2012, Varma et al, J. Biol. Chem. 2012). Potential links between development and cancer is now being evaluated as related genes may also uncover novel regulatory mechanisms for therapeutic targeting not only during development but also in other diseases associated with altered levels of Nkx2-1 such as neonatal respiratory distress, Brain-Lung-Thyroid syndrome, and acute respiratory distress syndrome.

ROLE OF NKX2.1-REGULATED MIRNAS IN MOUSE LUNG DEVELOPMENT AND DISEASES.
Many miRNAs are important in modulating lung gene expression and differentiation of progenitor cell populations. We are currently evaluating and characterizing potential Nkx2.1-regulated miRNAs identified in microRNA arrays by determining their patterns of expression and their effect in both cell proliferation and differentiation in lung development. We are also manipulating their expression in vitro and in vivo to validate their role in regulating lung genes and correlating their expression patterns and downstream targets in development and diseases because of the evidence that these genes may contribute to the abnormal lung phenotypes in Nkx2-1 mutant mouse models we are using and in cancer with the expectation that the ongoing analyses will reveal the underlying mechanisms driving cell proliferation, survival and differentiation in lung development and in lung diseases in which Nkx2-1 levels are altered. As the regulatory mechanisms to be studied in this project are also linked to tumor suppression our findings have the potential to contribute to the understanding and the control of lung tumor formation.

USE OF NOVEL NANO-EMULSION TECHNOLOGY FOR DRUG AND MIRNAS DELIVERIES.
Major challenges for development of a delivery system for miRNAs are the instability and their short biological half-life. To overcome this, one needs to optimize the formulation with smart drug delivery systems made up of complexes particles size of molecules in the sub-micron range referred to as nanoparticles suitable for the treatment of patients.

Using this technology, we have developed a novel Nano emulsion technology drug delivery platform that can deliver a medication contained within these compositions. Our composition is either a liposomal or non-liposomal, stable Nano emulsion selectively taken up by cells by exploiting the aspect that the Nano-delivery system is made of natural substances such as oil, surfactants and water, natural non viral gene vector such as chitosan a promising delivery tools for polymer-based nanoparticles or the highly efficient catalyst gold nanoparticles because of their potential applications in biology and medicine. We have successfully used this system to introduce Tamoxifen and Dacarbazine into human cancer cells (Tagne et al, Mol. Pharm. 2008 5(2): 280-6), (Tagne et al, Mol. Pharm. 2008 5(6): 1055-63)) and are currently expanding these technologies to facilitate introduction of genes and microRNAs into lung cells.

Our lab is currently using this technology to deliver Hydroxyurea for Sickle cell disease (SCD) a complex disorder characterized by clinical heterogeneity and pathologic evidence of intimal hyperplasia, proliferative changes and internal elastic lamina disruption across vascular beds so do Pulmonary hypertension (PH), an independent risk factor for mortality in the suffering patients and other growth factors. We plan to utilize this technology with our endothelial cell cultures. This represents the first attempt at direct gene manipulation of the endothelium using Nano-technology and promises to advance the therapeutic options for these patients.

Our design Nano emulsion based technology is capable of selectively targeting the cells/organ and delivering a combination of active miRs molecules with some tagged with fluorescent reporter or imaging agent(s) for live imaging.

NB: Our lab is part of the NANOTHERANOSTIC PLATFORMS FOR CANCER AND VASCULAR DISEASE Boston University ARC with multiple projects.

 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Tagne JB, Mohtar OR, Campbell JD, Lakshminarayanan M, Huang J, Hinds AC, Lu J, Ramirez MI. Transcription factor and microRNA interactions in lung cells: an inhibitory link between NK2 homeobox 1, miR-200c and the developmental and oncogenic factors Nfib and Myb. Respir Res. 2015; 16:22. PMID: 25763778.
    View in: PubMed
  2. Varma S, Cao Y, Tagne JB, Lakshminarayanan M, Li J, Friedman TB, Morell RJ, Warburton D, Kotton DN, Ramirez MI. The transcription factors Grainyhead-like 2 and NK2-homeobox 1 form a regulatory loop that coordinates lung epithelial cell morphogenesis and differentiation. J Biol Chem. 2012 Oct 26; 287(44):37282-95. PMID: 22955271.
    View in: PubMed
  3. Tagne JB, Gupta S, Gower AC, Shen SS, Varma S, Lakshminarayanan M, Cao Y, Spira A, Volkert TL, Ramirez MI. Genome-wide analyses of Nkx2-1 binding to transcriptional target genes uncover novel regulatory patterns conserved in lung development and tumors. PLoS One. 2012; 7(1):e29907. PMID: 22242187.
    View in: PubMed
  4. Kakumanu S, Tagne JB, Wilson TA, Nicolosi RJ. A nanoemulsion formulation of dacarbazine reduces tumor size in a xenograft mouse epidermoid carcinoma model compared to dacarbazine suspension. Nanomedicine. 2011 Jun; 7(3):277-83. PMID: 21215333.
    View in: PubMed
  5. Cao Y, Vo T, Millien G, Tagne JB, Kotton D, Mason RJ, Williams MC, Ramirez MI. Epigenetic mechanisms modulate thyroid transcription factor 1-mediated transcription of the surfactant protein B gene. J Biol Chem. 2010 Jan 15; 285(3):2152-64. PMID: 19906647.
    View in: PubMed
  6. Tagne JB, Kakumanu S, Nicolosi RJ. Nanoemulsion preparations of the anticancer drug dacarbazine significantly increase its efficacy in a xenograft mouse melanoma model. Mol Pharm. 2008 Nov-Dec; 5(6):1055-63. PMID: 19434855.
    View in: PubMed
  7. Tagne JB, Kakumanu S, Ortiz D, Shea T, Nicolosi RJ. A nanoemulsion formulation of tamoxifen increases its efficacy in a breast cancer cell line. Mol Pharm. 2008 Mar-Apr; 5(2):280-6. PMID: 18171014.
    View in: PubMed
  8. Kuo F, Kotyla T, Wilson T, Kifle L, Panagiotou T, Gruverman I, Tagne JB, Shea T, Nicolosi R. A nanoemulsion of an anti-oxidant synergy formulation reduces tumor growth rate in neuroblastoma-bearing nude mice. J Exp Ther Oncol. 2007; 6(2):129-35. PMID: 17407971.
    View in: PubMed
  9. Workman CT, Mak HC, McCuine S, Tagne JB, Agarwal M, Ozier O, Begley TJ, Samson LD, Ideker T. A systems approach to mapping DNA damage response pathways. Science. 2006 May 19; 312(5776):1054-9. PMID: 16709784.
    View in: PubMed
  10. Tachibana C, Yoo JY, Tagne JB, Kacherovsky N, Lee TI, Young ET. Combined global localization analysis and transcriptome data identify genes that are directly coregulated by Adr1 and Cat8. Mol Cell Biol. 2005 Mar; 25(6):2138-46. PMID: 15743812.
    View in: PubMed
  11. Harbison CT, Gordon DB, Lee TI, Rinaldi NJ, Macisaac KD, Danford TW, Hannett NM, Tagne JB, Reynolds DB, Yoo J, Jennings EG, Zeitlinger J, Pokholok DK, Kellis M, Rolfe PA, Takusagawa KT, Lander ES, Gifford DK, Fraenkel E, Young RA. Transcriptional regulatory code of a eukaryotic genome. Nature. 2004 Sep 2; 431(7004):99-104. PMID: 15343339.
    View in: PubMed
  12. Kleene KC, Cataldo L, Mastrangelo MA, Tagne JB. Alternative patterns of transcription and translation of the ribosomal protein L32 mRNA in somatic and spermatogenic cells in mice. Exp Cell Res. 2003 Nov 15; 291(1):101-10. PMID: 14597412.
    View in: PubMed
  13. Lee TI, Rinaldi NJ, Robert F, Odom DT, Bar-Joseph Z, Gerber GK, Hannett NM, Harbison CT, Thompson CM, Simon I, Zeitlinger J, Jennings EG, Murray HL, Gordon DB, Ren B, Wyrick JJ, Tagne JB, Volkert TL, Fraenkel E, Gifford DK, Young RA. Transcriptional regulatory networks in Saccharomyces cerevisiae. Science. 2002 Oct 25; 298(5594):799-804. PMID: 12399584.
    View in: PubMed
Jean-Bosco's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department